Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

tion can be administered safely in this patient population. In the trial, no neuropathy greater than grade 1 has been observed in all patients treated, including four patients who received a cumulative picoplatin dose of greater than 900 mg/m2. The Company plans to present data from the Phase 1 trial at scientific meetings in 2008.

The platinum therapy oxaliplatin is an integral component of chemotherapy regimens which have become a standard treatment for metastatic CRC. The associated side effects, most notably, neuropathy, can significantly impair the quality of life of patients and limits the optimal use of oxaliplatin. According to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology, discontinuation of oxaliplatin from the FOLFOX regimen (in which oxaliplatin is given in combination with 5- fluorouracil and leucovorin) should be strongly considered after three months of therapy, or sooner if significant neurotoxicity develops.

Phase 2 Colorectal Cancer Trial Design

The Phase 2 trial will include approximately 100 patients with metastatic CRC randomized to either picoplatin (150 mg/m2) given once every four weeks in combination with 5-fluorouracil and leucovorin in the FOLPI regimen or oxaliplatin in combination with 5-fluorouracil and leucovorin in the FOLFOX regimen. The trial will evaluate whether FOLPI demonstrates equivalent or better efficacy than FOLFOX without the substantial neurotoxicity associated with oxaliplatin. Efficacy and safety assessment will include objective tumor response, duration of response, progression-free survival, overall survival and assessment of peripheral neuropathy. The trial will be conducted at approximately 25 clinical sites and is expected to complete enrollment in the first half of 2008. The Company currently expects to have early tumor response data and long-term safety data in the first half of 2008 and intends to submit the data for presentation at scientific confere
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
(Date:7/31/2015)... -- According to a new market research report ... Ethylene Oxide, Filtration, E-beam, Gamma), Services (Onsite & Offsite), Consumables ... Forecast to 2020", published by MarketsandMarkets, The Sterilization Equipment Market ... at a CAGR of 7.6%.from 2015 to 2020. ... ables and 37 F ...
(Date:7/31/2015)... PORTLAND, Ore., July 31, 2015  Semler Scientific, Inc. ... and testing services to healthcare insurers and physician groups, ... June 30, 2015. "In the second ... over year revenue growth of 54%, quarter over quarter ... of the installed base of FloChec® units of 18%," ...
Breaking Medicine Technology:NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 2Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 3Sterilization Equipment Market is Expected to Reach USD 6.1 Billion by 2020 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
(Date:7/31/2015)... , ... July 31, 2015 , ... Transfinder, a software ... , Total sales were up 16 percent year-over-year for the first six months ended ... Civitella said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just ... industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at ... attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... research firm, has been recognized in the 2015 Aster Awards national competition for ... healthcare organization serving Ocean City and surrounding communities in Coastal Maryland and Southern ...
(Date:7/31/2015)... ... , ... The 2015 ALS Ice Bucket Challenge will officially get underway today ... honor Ice Bucket co-founders Pat Quinn and Pete Frates, the ALS community and Lou ... among the ALS organizations to find treatments and cures for the disease. , ...
(Date:7/31/2015)... ... , ... Like nearly every other form of surgery, it shouldn't come as ... and less intrusive and painful. Leading these advances in the United States has ... stands as the only doctor in the United States who is qualified to practice, ...
Breaking Medicine News(10 mins):Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2
... A group of researchers from Stanford have identified the nitric ... chemical events gradually resulting in the development of an embryo.He ... the sperm.// ,The research is based on the ... purple invertebrates found in the Pacific Ocean just a few ...
... flowing smoothly after angioplasty shows surprising success in early testing. ... the drug-coated stent. //In testing on 50 patients over 3 ... ,More than 2 million Americans undergo angioplasty annually, ... most of them if these promising results hold up in ...
... honey could prove effective in arresting the dental plaque ... New Zealand researcher will report at the American Association// ... enzyme in honey that produces hydrogen peroxide is the ... Dr. Peter C. Molan, associate professor of biochemistry at ...
... of Medicine have recently found that the brain's 'nose plug' ... stop smelling something, even though the odour is still there.// ... journal Science show that a protein called CNGA4 helps plug ... neurons is to detect smells and send that information to ...
... close to signing a deal to acquire the 51.5 per ... drugmaker Abbott Laboratories Inc. An industry source who declined to ... next few days to buy the stake in Abbott Laboratories ... officials from the company’s regional office in singapore will be ...
... heart surgery for patients in their mid-eighties and beyond ... for the elderly.// ,According to Dr. Todd Rosengart, ... heart surgery, if indicated, is safe and will improve ... of cardiac surgery at Southeastern Healthcare in Illinois. ...
Cached Medicine News:Health News:The route to fertilization, 2Health News:Heart Surgery Is Getting Safer for the Old 2
... designed to help you achieve one important ... procedure. All needles are engineered for exceptional ... for smooth entry and exit. A broad ... an ideal match with procedural needs and ...
... implant is a combination of innovative design, ... makes TheraSeed® treatment an ideal choice for ... that every TheraSeed® implant order is backed ... required by clinicians who must meet the ...
... Every Bard BrachyStar® Needle is designed to ... efficient and clinically effective brachytherapy procedure. All ... ultra-sharp tips and polished surfaces for smooth ... needle configurations and sizes assures an ideal ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
Medicine Products: